Vector Bioscience Cambridge
Vector Bioscience is a biotechnology company focused on redefining biologics delivery through a machine-learning-powered drug delivery platform. Their proprietary Nanoshuttle technology aims to transform oncology treatments with precision-targeted delivery, minimizing side effects and maximizing drug uptake. The company tailors delivery systems for specific cancers, achieving high local concentrations of therapeutics that are traditionally difficult to formulate. Their approach involves data-driven selection of cargoes and antibodies, supported by dry lab (ML-enabled material selection) and wet lab (engineering of cargo and drug loading) processes. Vector Bioscience is developing novel medical treatments for precision medicines and is progressing through preclinical and clinical stages for various cancers, including pancreatic, lung, glioblastoma, colorectal, prostate, and breast cancer. They have filed 3 patents and secured non-dilutive funding. The company emphasizes a culture of pushing boundaries and prioritizing excellence, with a vision to provide ultimate precision medicine and a mission to improve patient treatments by maximizing efficacy and minimizing side effects.
Vector Bioscience Cambridge
Vector Bioscience is a biotechnology company focused on redefining biologics delivery through a machine-learning-powered drug delivery platform. Their proprietary Nanoshuttle technology aims to transform oncology treatments with precision-targeted delivery, minimizing side effects and maximizing drug uptake. The company tailors delivery systems for specific cancers, achieving high local concentrations of therapeutics that are traditionally difficult to formulate. Their approach involves data-driven selection of cargoes and antibodies, supported by dry lab (ML-enabled material selection) and wet lab (engineering of cargo and drug loading) processes. Vector Bioscience is developing novel medical treatments for precision medicines and is progressing through preclinical and clinical stages for various cancers, including pancreatic, lung, glioblastoma, colorectal, prostate, and breast cancer. They have filed 3 patents and secured non-dilutive funding. The company emphasizes a culture of pushing boundaries and prioritizing excellence, with a vision to provide ultimate precision medicine and a mission to improve patient treatments by maximizing efficacy and minimizing side effects.